These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 17610348)

  • 21. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
    Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
    Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRP, but not TNF-α or IL-6, decreases after weight loss in patients with morbid obesity exposed to intensive weight reduction and balneological treatment.
    Rość D; Adamczyk P; Boinska J; Szafkowski R; Ponikowska I; Stankowska K; Góralczyk B; Ruszkowska-Ciastek B
    J Zhejiang Univ Sci B; 2015 May; 16(5):404-11. PubMed ID: 25990058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load.
    Derosa G; Cicero AF; Fogari E; D'Angelo A; Bonaventura A; Romano D; Maffioli P
    J Clin Lipidol; 2012; 6(6):553-64. PubMed ID: 23312051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S; Geiss HC; Otto C; Parhofer KG
    Am J Cardiol; 2006 Jul; 98(1):66-9. PubMed ID: 16784923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose.
    Krysiak R; Okopien B
    Metabolism; 2013 Jan; 62(1):39-43. PubMed ID: 22841520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
    Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
    Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease.
    Matsuo Y; Hashizume T; Shioji S; Akasaka T
    Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
    Kaya C; Pabuccu R; Cengiz SD; Dünder I
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):161-6. PubMed ID: 20146169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Evaluation of Metformin and/or Metformin Plus a New Polysaccharide Complex in Treating Severe Hyperinsulinism and Insulin Resistance in Obese Children and Adolescents with Metabolic Syndrome.
    Stagi S; Ricci F; Bianconi M; Sammarco MA; Municchi G; Toni S; Lenzi L; Verrotti A; de Martino M
    Nutrients; 2017 May; 9(5):. PubMed ID: 28531113
    [No Abstract]   [Full Text] [Related]  

  • 34. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
    Fogari R; Preti P; Zoppi A; Lazzari P; Corradi L; Fogari E; Ciccarelli L; Derosa G
    Eur J Clin Pharmacol; 2006 Oct; 62(10):817-22. PubMed ID: 16896785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
    Mulder DJ; van Haelst PL; Wobbes MH; Gans RO; Zijlstra F; May JF; Smit AJ; Tervaert JW; van Doormaal JJ
    Cardiovasc Drugs Ther; 2007 Apr; 21(2):91-7. PubMed ID: 17342417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Metformin hydrochloride ameliorates adiponectin levels and insulin sensitivity in adolescents with metabolic syndrome].
    Liang L; Fu JF; Zou CC; Hong F; Wang CL; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Feb; 44(2):118-21. PubMed ID: 16624028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
    Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
    Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.